Vertex Pharmaceuticals (VRTX) Free Cash Flow (2009 - 2026)

Vertex Pharmaceuticals' Free Cash Flow history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 66.37% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $3.7 billion, a 396.75% increase from a year earlier, with the FY2025 full-year figure at $3.2 billion, up 504.13% from the prior year.
• Free Cash Flow grew to $1.3 billion in Q1 2026 per VRTX's latest filing, from $348.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $1.3 billion in Q3 2024 and bottomed at -$3.8 billion in Q2 2024.
• The 5-year median for Free Cash Flow is $927.4 million (2025), against an average of $644.7 million.
• Across the five-year window, Free Cash Flow soared 535.3% in 2022 and plunged 455.66% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at $1.0 billion in 2022, then tumbled by 83.11% to $176.5 million in 2023, then surged by 178.75% to $492.0 million in 2024, then fell by 29.15% to $348.6 million in 2025, then soared by 271.4% to $1.3 billion in 2026.
• Per Business Quant, the three latest VRTX Free Cash Flow figures stand at $1.3 billion (Q1 2026), $348.6 million (Q4 2025), and $1.1 billion (Q3 2025).